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Upper Respiratory Tract Symptoms, Renal Involvement 
and Vasculitis: A Case Report and Review of 
Wegener Granulomatosis
Mohd Shahrir Mohamed Said
Abstract
Wegener’s Granulomatosis is a condition associated with systemic 
vasculitis which can present with upper respiratory tract symptoms 
initially.  On  September  2001,  a  15-year-old  girl  presented  with 
symptoms of nasal block for 3 weeks. She later developed joint 
pains and worsening renal status requiring dialysis. A renal biopsy 
was performed which showed pauci-immune cresentric glomerulo-
nephritis. Her cANCA levels were positive. She was treated with 
oral cyclophosphamide and steroids and later responded.
Keywords: Wegener  granulomatosis; Young  girl;  Cyclophopha-
mide; cANCA
Introduction
Wegener’s Granulomatosis (WG) is a condition associated 
with generalized vasculitis and was first reported by Heinz 
Klinger and Frederick Wegener. Appropriately, Wegener de-
scribed the lesion as ‘rhinogenic granulomatosis with special 
involvement of the arterial system and the kidneys.’ The pe-
culiar aspect of this case was that the patient was a girl who 
was only 15 years of age. In fact there was only one case 
report so far of WG in a 10-year-old girl. The diagnosis was 
clinched by the typical renal biopsy.
 
Case Report
Miss CYY was a 15-year-old schoolgirl who was referred 
from Fatimah Hospital. She first presented with a three week 
history of bilateral nasal block. She then developed joint 
pains.  She  also  developed  oral  ulcers  and  maculopapular 
rashes over her left elbow, left ankle and left popliteal fossa. 
Her eyes became red and watery with a clear discharge. She 
also complained of photophobia and insomnia and gastroin-
testinal symptoms of anorexia and nausea. However, there 
was no pruritus, vomiting or change of behaviour. 
On examination, she was pale, with minimal ankle oe-
dema. Jugular venous pressure was not raised. There were 
oral ulcers and her eyes revealed injected conjunctiva but no 
hemorrhages. Eye examination revealed sluggish papillary 
reflex, injected sclera and haziness over the anterior cham-
ber. Cardiovascular, respiratory and abdominal examinations 
were all essentially normal. There was a purpuric rash over 
her right elbow, left ankle and left popliteal fossa.
Her full blood count revealed an Hb of 7.6 g/dL, to-
tal white cell count of 27,800 /ml and a platelet count of 
840,000 /ml. ESR was 138 mm/hr. C reactive protein was 
elevated at 199 mg/L. On admission, blood urea was 16.5 
mmol/L which progressively increased to a level of 46.8 
mmol/L. Se Creatinine was 680.6 mmol/L. Urine examina-
tion revealed numerous red blood cells and no albuminuria. 
There were no red cell casts and white cell casts. No urine 
phase contrast was done. The cytoplasmic ANCA was posi-
tive. Anti dsDNA and ANF were negative. Serum C3 and C4 
were low. Hepatits BsAg was negative and so was the HIV 
serology. Both Coomb’s tests direct and indirect were nega-
tive.  Oesophago-Gastro-Duodenalsopy  (OGDS)  revealed 
multiple hemorrhagic spots of the gastric walls. No gastric 
biopsy was done. VDRL was negative. Spiral CT scan of the 
sinuses revealed bilateral maxillary and ethmoid sinusitis.
Renal biopsy following adequate dialysis revealed fi-
brocellular and sclerotic crescent global involvement. There 
were 28 glomeruli. Among them 24 glomeruli showed par-
tial crescent formation with compressed glomerular capillary 
loops. There was also extension of the fibrosis into periglo-
merular tissue on silver staining. There were no intracapillary 
or granuloma formation. The tubules showed degenerative 
and regenerative changes with occasional white blood cell 
cast. The interstitium was edematous with a dense inflamma-
tory infiltrate consisting of lymphocytes, plasma cells, his-
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tiocytes and neutrophils. Immunoflourescent study revealed 
weak segmental glomerular capillary wall staining with IgG, 
IgM and C3. IgA was negative. Blood vessels showed no 
reactivity. The histologic diagnosis was pauci-imunne cre-
sentric glomerulonephritis consistent with WG. 
She  was  pulsed  with  intravenous  methylprednisolone 
250 mg daily for 3 days followed by oral prednisolone and 
intravenous  cyclophosphamide.  Later,  oral  cyclophospha-
mide was started. She responded well to treatment. 
Discussion
  
The term ‘systemic vasculitis’ can occur as a primary event, 
e.g. in the ANCA associated vasculitides, or secondary to 
other  established  diseases  (secondary  vasculitis)  e.g.  col-
lagen vascular disorders. The classification of vasculitides 
was developed by the Chapel Hill Conference in 1992 [1] 
and was based on: (1) clinical and histopathologic features; 
(2) the size of the predominant vessel involved; (3) the pres-
ence of serologic markers and other immune phenomena; (4) 
and/or the affected tissue (for exemple, immune deposits), as 
demonstrated by immunohistochemistry.
There are four types of hypersensitive reactions accord-
ing to Coombs and Gell: (I) immediate hypersensitivity; (II) 
antibody mediated hypersensitivity; (III) immune complex 
mediated hypersensitivity; and (IV) T-cell mediated hyper-
sensitivity. Vasculitis is a type II reaction [1].
There are three types of anti neutrophil cytoplasmic anti-
bodies (ANCA) known currently. The first one is the classic 
granular cytoplasmic pattern (cANCA). The second is the 
perinuclear fluorescence pattern (pANCA). And the third is 
the atypical ANCA (aANCA) [1]. 
In WG, cANCA gives a 95% specificity. However, its 
level depends also on the extent and phase of the disease. In 
the ‘initial phase’ whereby WG is localized to the upper and 
lower respiratory tracts, cANCA confers a 50% specificity. 
In the generalized form the specificity is 100%. In complete 
remission cANCA is not detectable.
The hallmark of WG includes the clinical feature of pul-
monary-renal  vasculitis,  immunohistochemical  (pauci-im-
mune vascultis or glomerulonephritis) and serologic mark-
ers (cANCA). Renal biopsy would show a necrotizing (GN) 
with crescent formation as typically depicted by this case 
report. Immunohistochemistry studies of the renal tissue re-
veals a pauci-immune picture. However, in Goodpasture’s 
syndrome and Henoch-Schonlein purpura there are linear 
IgG deposits in the capillary and mesangium along glomeru-
lar basement membrane and IgA deposits respectively [1].
WG is associated very closely with an enzyme called 
Proteinase 3 (PR3). PR3 is stored in the azurophilic granules 
of human polymorphonuclear leucocytes and monocytes and 
serve as autoantigens for vasculitis associated ANCA. PR3 
also controls growth and differentiation of leukaemic cells, 
micorbacteriacidal activity and activation of cytokines.
ANCA is a pathogenic factor in inflammatory processes 
that underlie necrotizing vasculitis. There are four hypoth-
eses to the pathogenensis of ANCA in vasculitis process: (1) 
The first hypothesis states that it is responsible for interact-
ing with effector cells and rarely interferes with physiologic 
functions of the target antigen [1]. (2) The second hypothesis 
states that ANCA binds to PR3 reducing its proteolytic ac-
tivity while at the same time preventing immune complex 
formation and complete inactivation by alpha-1-antitrypsin. 
Dolman et al [2] postulate that the inhibitory effect of ANCA 
on  PR3-alpha-1-anti-trypsin  complex  formation  correlates 
with clinical activity in WG patients [2]. (3) The third pos-
tulates that ANCA can activate primed PMN to release oxy-
gen radicals and lysosomal enzymes [3, 4]. (4) The fourth 
is  known  as  the ANCA-cytokine  sequence  theory  [5].  It 
proposes that priming doses of proinflammatory cytokines 
induce surface expression of ANCA target antigens. Binding 
of ANCA to these antigens leads to full neutrophil activation 
and endothelial cell injury and subsequent vascular injury. 
It was demonstrated in vitro and ex vivo by flow cytometry 
that TNF alpha and Interleukin 8 act synergistically to in-
duce a translocation of PR3 from intragrannular loci to the 
cell surface of PMN. In murine models, it was demonstrated 
that monoclonal ANCA IgG binds to PR3 and engages Fc-
gamma-RIIa and activate PMN via receptor mediated signal 
transduction system.
In active ANCA associated glomerulonephritis resident 
cells, endothelial cells and infiltrating mononuclear cell ex-
press cytokines, (Interleukin 1, Interleukin 2, Tumor Necro-
sis Factor alpha, Interferon gamma, Platlet Derived Growth 
Factor and Tumor Growth Factor beta), growth factor recep-
tors, (Tumor Necrosis Factor receptor, Interleukin 1 receptor 
type II, Interleukin 2 receptor, Interferon receptor and Platlet 
Derived Growth Factor beta receptor), and adhesion mol-
ecules, (ICAM-1 and ELAM-1) [4, 5].
Renal lesions in WG demonstrate the abundance and in-
tensity of expression of ICAM-1 which correlate with the 
presence of glomerular crescents and the number of LFA-1 
positive (CD11a) leucocytes. Thus, the serum levels of these 
soluble adhesion molecules correlate with disease activity 
and renal impairment [5].
Genetically, WG has some correlation with HLA class 
II. Persitence of ANCA correlates with presence of DQw7 
and  DR4  haplotypes.  The  cANCA  is  associated  with  in-
creased frequency of the Z allele [6].
Coxsackie B3 and Parvovirus-B19 had been postulated 
as environmental triggers of ANCA and /or WG. Stegemann 
et al [7] had reported association of chronic nasal carriage 
of Staphylococcus aureus with higher relapse rates in WG.
In a study conducted on 477 WG patients it was found 
23 of these patients had malignancies. Seven out of 23 had 
renal cell carcinoma [1].
As for drug induced ANCA associated vasculitis, pro-
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pylthiouracil and hydralazine were known causes for this 
phenomenon.
There were many theories which try to explain the ba-
sis of autoimmune diseases. One such popular theory is the 
idiotype-anti-idiotype reactions. It was believed that autoan-
tibody formation is regulated by this idiotype-anti-idiotype 
reactions network. Defect in the network results in produc-
tion of autoantibodies [8, 4].
According to Hoffman et al [9] and Barth et al, airway 
stimulation form a variety of sources triggers a neutrophilic 
alveolar response in predisposed patients to develop WG and 
to develop ANCA, which may result in enhanced recruitment 
and activation of monocytes, lymphocytes and eosinophils. 
However, no specific sources were actually identified.
At presentation 80% of WG patients have no renal in-
volvement. However, when patients present with destructive, 
sterile inflammatory lesions of the upper and lower respira-
tory tract and glomerulonephritis, WG must always be ruled 
out. In 50% of these patients there could be a 3 to 6 months 
delay in diagnosis. About 73% of these patients will present 
with nasal, sinus, tracheal and/or ear abnormalities. Often, 
these complaints will be attributed to upper respiratory infec-
tions or allergy. Recurrent epistaxis, mucosal ulcerations, na-
sal septal deformities or perforations will lead to a more ex-
tensive evaluation. Other ENT symptoms include: sinusitis, 
nasal diseases, otitis media, hearing loss, subglottic stenosis, 
ear pain and oral lesions, all in decreasing frequency. Lung 
presentation includes: infiltrates, nodules, hemoptysis and 
pleuritis. Eye diseases include: conjunctivitis, dacrocystits, 
scleritis, proptosis, eye pain, visual loss, retinal and corneal 
diseases also in decreasing frequency. Only 18% will present 
with glomerulonephritis. However, 75% of WG patient will 
eventually develop GN [1].
Abnormal investigations such as red blood cells in urine, 
elevated erythrocyte sedimentation rate (ESR), anemia, chest 
X ray showing pulmonary infiltrates and positive cANCA 
may prompt the pursuit of a definitive tissue biopsy [1].
Increases in ESR (Westergren method) correlates with 
disease activity in 80% of patients [1]. Anemia is common 
with thrombocytosis. The principle target of cANCA is PR3. 
Numerous studies utilizing either indirect immunofloures-
cent (IIF) and/or enzyme linked immunassay (ELISA) have 
indicated that cANCA and positive ELISA PR3 reactions 
have a specificity for WG about 98%. When neutrophiles 
for IIF ANCA are fixed in formaldehyde the ANCA-related 
antigens remained in the cytoplasm. When fixed with etha-
nol three types of patterns emerged: cANCA, pANCA and 
aANCA [1].
Titres of cANCA correlates with disease activity. In a 
study by Boomsma et al [10], who did a study on prediction 
of relapses in WG by measurement of ANCA levels, they 
found that serial measurements of ANCA levels is valuable 
for early prediction of relapses in patients with WG. In a pro-
spective study involving 100 patients with WG form 1996 to 
1998, there were 37 patients who relapsed. Out of these 37 
patients, 34 showed a rise in their ANCA levels [11].
In a prospective study done by Aasarod K et al [12], a 
renal hispathological study was done on 94 patients. Two bi-
opsies were done, one at initial diagnosis and the other after 
3 years. The study took 42.5 months and revealed segmental 
necrotizing glomerulonephritis and extracapillary prolifera-
tion, in 85.1% and 91.5% respectively in these biopsies. All 
7.4% patients who had normal serum creatinine and urinary 
protein excretion less than 0.5g/day had crescents; and six 
out of 7.4% had segmental glomerular necrosis. This study 
also showed that renal biopsy is of value in defining renal 
involvement in WG, but it is of limited help in early stage 
of the disease and in predicting renal outcome. However, 
the second part of the conclusion was not valid because only 
14% of the WG patients turned up for the second biopsy. 
Differential  diagnosies  includes  Churg-Strauss  syn-
drome  (CSS),  angiocentric  immunoproliferative  lesions 
(AIL), Goodpasture’s disease and infective causes for de-
structive upper or lower respiratory tracts. In CSS the clini-
cal features include asthma and marked eosinophilia. AIL 
includes angiocentric and angiodestructive infiltrates which 
are polymorphous and include atypical lymphocytes. Grade 
I AIL resembles WG but the renal involvement is interstitial 
nephritis and not GN. Goodpasture’s disease has anti glo-
merular  basement  membrane  antibodies.  Mycobacterium, 
fungi, actinomycosis and syphilis, squamous cell carcinoma, 
extranodal lymphoma and cocaine abuse can resemble local 
WG.
In this patient the management consisted of T. predniso-
lone 60 mg daily and oral cyclosphosphamide 100 mg od for 
six months. The aim of cyclophosphamide is to suppress the 
total white cell count to a level of 4,000 cells/dL. Patient was 
monitored monthly with full blood counts.
Current management of WG consists of oral cyclophos-
phamide (CP) 2 mg/kg/day in combination with oral pred-
nisolone 1 mg/kg/day. Daily prednisolone is continued for 
four weeks and tailed down gradually over 1 to 2 months 
before converting it to an alternate day regimen. Then the 
dose is further tapered down till patient is solely on CP (1). 
The effect of CP is seen within 1 to 2 weeks. However, in se-
vere disease CP is started at 3 - 5 mg/kg/day using the leuco-
cyte count as a guide for dosage adjustments. Prednisolone 
is given from 2 to 15 mg/kg/day [1].
One dilemma about CP is the route of administration in-
travenous pulsed CP and oral CP. According to Haubitz et al 
[13] IV CP is just as effective as oral CP and associated with 
fewer side effects with ANCA associated vasculitis and renal 
involvement. Again this is only based on serum creatinines 
and not on biopsy results. In a study done by Guillevin et al 
[14], IV CP was as effective as oral CP but in the long term, 
treatment with IV pulse CP did not maintain remission or 
prevent relapses as effectively as oral CP. Compared to 13% 
of 23 patients on oral CP and GC, 59.2% of 27 patients on 
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IV CP and GC relapsed. This study was a prospective multi-
center randomized trial.
In a report involving pregnant WG patients, done by Lu-
isiri et al [15], the patient was treated with GC and CP suc-
cessfully. He also reported that there were 10 similar cases in 
literature and the disease can have a more aggressive course 
in pregnancy.
Other agents that have been used include: methotrexate 
(MTX), leflunomide, cotrimoxazole in localized WG, etan-
ercept,  mycophenolate,  15-deoxyspergualin,  intravenous 
immunoglobulin, tumor necrosis factor, anti-lymphocyte di-
rected therapy, anti-adhesion molecule directed therapy and 
immunoablation using high dose cytotoxic medication with 
or without stem cell rescue. There is also suggested sequen-
tial chemotherapy involving CP followed by azathrioprine 
and CP followed by methotrexate [11, 16-19]. 
In the study done by Langford et al [17], he used a 
combination of MTX and glucocorticoids (GC) in treating 
patients with renal outcome of WG. The study involved 42 
patients of whom 21 developed GN. Baseline serum creati-
nine was 1.4 mg/dL. Twenty out of 21 patients achieved re-
nal remission. After the follow up period, this study showed 
positive results for these patients. However, the study was 
too small to make any impact on the future management of 
WG. Furthermore, it did not monitor ANCA levels. There 
was  also  no  renal  biopsy  follow-up.  Langford  et  al  [18] 
also conducted another study that used MTX as a remission 
maintenance regimen after using CP and GC as a remission 
induction. Of 31 patients, 16% relapsed. Again, this does not 
look promising. The studies with other agents involved very 
few patients.
Morbidity in WG occurs as a result of disease only, from 
the disease plus treatment and from the treatment only.
In the NIH study, permanent disease related morbid-
ity included chronic renal insufficiency (42%), hearing loss 
(35%), nasal deformity (28%), tracheal stenosis (13%) and 
visual loss (8%). About 10% required dialysis. Renal trans-
plant patients must be in remission before operation. Most of 
these patients achieved remission [1].
The  only  pathology  associated  with  the  disease  plus 
treatment is progressive pulmonary insufficiency. There is 
no study done to prove this as yet.
Patients of CP may have hair loss (20%), CP cystitis 
(50%), bladder cancer (5%) and myelodysplasia (2%). Side 
effects related to GC include DM (8%), cataracts (21%), os-
teoporosis fractures (11%) and aseptic necrosis (3%) [1].
The malignancy rate of WG was compared to the Na-
tional Cancer Institute Registry. There is an overall 2.4-fold 
increase in malignancy, a 33-fold increase in bladder cancer 
and an 11-fold increase in lymphoma. There was latency of 
seven months from the start of CP administration to the oc-
currence of transitional cell carcinoma of the bladder. The 
occurrence of atypical cells in the urine is suggestive of this 
phenomenon. A cystoscopy and appropriate biopsy should 
be carried out. If the tissue biopsy is normal then a 1 - 3 
yearly cystoscopy should be carried out for surveillance [1].
Pneumocystis  carinii  Pneumonia  (PCP)  is  a  frequent 
complication in these patients. Of 180 patients 6% devel-
oped PCP. These patients all received CP treatment in the 
early phase and were lymphopenic. Chemoprophylaxis of 
PCP has been suggested [1].
All in all, the effective treatment of WG must include 
complete remission and prevention of relapses. Perhaps in 
the near future, when the pathogenesis of WG can truly be 
explained, we could develop a better agent for the treatment 
of WG.
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